The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Tilray Exports Medical Cannabis Extracts to Switzerland
Dec. 17, 2019 05:11AM PST
Cannabis Investing NewsTilray has successfully exported medical cannabis extracts to Switzerland from its GMP-certified production facility.
Tilray (NASDAQ:TLRY) announced on Tuesday (December 17) it has successfully exported medical cannabis extracts to Switzerland from its good manufacturing practices (GMP)-certified production facility.
As quoted in the press release:
We’re proud to deliver Tilray’s medical cannabis to Swiss patients in need as we continue our expansion into Europe and around the globe,” says Sascha Mielcarek, Tilray’s Managing Director in Europe. “Tilray is committed to quality and patient safety and we look forward to significantly improving the quality of lives of Swiss patients through our medical cannabis products.”
The import and export permits were received in early December 2019, with the shipment of Tilray’s medical cannabis extracts successfully arriving in Switzerland on December 13. Following this first shipment of extracts, Tilray also anticipates exporting dried medical cannabis to Switzerland, offering patients an assortment of form factors to meet their varying medical indications.
Click here to read the full press release.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.